Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
$10.98
-0.7%
$8.98
$4.93
$14.44
$937.88M0.721.19 million shs762,981 shs
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
$10.93
-6.2%
$10.81
$7.80
$28.09
$596.08MN/A590,978 shs345,263 shs
Xencor, Inc. stock logo
XNCR
Xencor
$8.97
-1.1%
$8.50
$7.16
$27.24
$638.40M0.85687,519 shs417,365 shs
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
$4.31
-0.2%
$4.52
$3.55
$16.11
$195.17M0.51293,920 shs157,975 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
0.00%-1.17%+21.59%+22.68%+85.47%
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
0.00%+12.56%+15.91%-10.12%+1,092,999,900.00%
Xencor, Inc. stock logo
XNCR
Xencor
0.00%+1.59%+7.30%-7.53%-54.83%
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
0.00%-1.15%-6.91%-8.10%-65.74%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
3.9108 of 5 stars
3.71.00.04.72.50.80.6
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
2.005 of 5 stars
3.50.00.00.02.10.80.6
Xencor, Inc. stock logo
XNCR
Xencor
4.1173 of 5 stars
3.45.00.03.90.00.81.3
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
3.6743 of 5 stars
4.45.00.00.00.62.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
3.33
Buy$44.00300.73% Upside
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
3.00
Buy$31.86191.48% Upside
Xencor, Inc. stock logo
XNCR
Xencor
2.75
Moderate Buy$28.00212.15% Upside
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
2.82
Moderate Buy$15.60261.95% Upside

Current Analyst Ratings Breakdown

Latest YMAB, BCAX, XNCR, and AVXL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/29/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$20.00 ➝ $15.00
5/28/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$21.00 ➝ $18.00
5/23/2025
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderweight ➝ Equal Weight$8.00
5/23/2025
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$30.00
5/19/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $11.00
5/16/2025
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$44.00 ➝ $41.00
5/14/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$18.00 ➝ $14.00
5/14/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$21.00 ➝ $20.00
5/8/2025
Xencor, Inc. stock logo
XNCR
Xencor
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$22.00 ➝ $6.00
4/30/2025
Xencor, Inc. stock logo
XNCR
Xencor
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$31.00
4/22/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeNeutral ➝ Underperform$3.00
(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
N/AN/AN/AN/A$1.42 per shareN/A
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/AN/AN/AN/A$9.04 per shareN/A
Xencor, Inc. stock logo
XNCR
Xencor
$110.49M5.78N/AN/A$9.63 per share0.93
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
$87.68M2.23N/AN/A$2.05 per share2.10
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
-$43M-$0.55N/AN/AN/AN/A-40.93%-36.38%8/5/2025 (Estimated)
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
-$68MN/A0.00N/AN/AN/AN/AN/A8/12/2025 (Estimated)
Xencor, Inc. stock logo
XNCR
Xencor
-$232.62M-$3.06N/AN/AN/A-181.17%-31.94%-22.19%8/4/2025 (Estimated)
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
-$29.67M-$0.64N/AN/AN/A-31.84%-30.59%-22.70%8/11/2025 (Estimated)

Latest YMAB, BCAX, XNCR, and AVXL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
-$0.54N/AN/AN/AN/AN/A
8/11/2025Q2 2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
-$0.27N/AN/AN/A$18.40 millionN/A
8/5/2025Q3 2025
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
-$0.13N/AN/AN/AN/AN/A
8/4/2025Q2 2025
Xencor, Inc. stock logo
XNCR
Xencor
-$0.78N/AN/AN/A$22.59 millionN/A
5/13/2025Q2 2025
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
-$0.16-$0.13+$0.03-$0.13N/AN/A
5/13/2025Q1 2025
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
-$0.40-$0.68-$0.28-$0.68N/AN/A
5/13/2025Q1 2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
-$0.22-$0.12+$0.10-$0.12$19.97 million$20.90 million
5/8/2025Q1 2025
Xencor, Inc. stock logo
XNCR
Xencor
-$0.60-$0.66-$0.06-$0.66$23.44 million$32.73 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
N/AN/AN/AN/AN/A
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/AN/AN/AN/AN/A
Xencor, Inc. stock logo
XNCR
Xencor
N/AN/AN/AN/AN/A
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
N/A
6.74
6.74
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/A
24.62
24.62
Xencor, Inc. stock logo
XNCR
Xencor
0.16
5.89
5.89
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
N/A
4.77
4.35

Institutional Ownership

CompanyInstitutional Ownership
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
31.55%
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/A
Xencor, Inc. stock logo
XNCR
Xencor
N/A
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
70.85%

Insider Ownership

CompanyInsider Ownership
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
11.40%
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
15.50%
Xencor, Inc. stock logo
XNCR
Xencor
4.76%
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
19.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
4085.42 million75.68 millionOptionable
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
3254.54 million46.08 millionN/A
Xencor, Inc. stock logo
XNCR
Xencor
28071.17 million67.78 millionOptionable
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
15045.28 million36.36 millionOptionable

Recent News About These Companies

YMAB Y-mAbs Therapeutics, Inc. - Seeking Alpha
Y mAbs Therapeutics News (YMAB) - Investing.com
Y-mAbs Therapeutics announces presentation of PK data of CD38-SADA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Anavex Life Sciences stock logo

Anavex Life Sciences NASDAQ:AVXL

$10.98 -0.08 (-0.72%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$11.01 +0.03 (+0.27%)
As of 07/18/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Bicara Therapeutics stock logo

Bicara Therapeutics NASDAQ:BCAX

$10.93 -0.72 (-6.18%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$10.90 -0.03 (-0.27%)
As of 07/18/2025 06:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Xencor stock logo

Xencor NASDAQ:XNCR

$8.97 -0.10 (-1.10%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$8.97 0.00 (0.00%)
As of 07/18/2025 04:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

Y-mAbs Therapeutics stock logo

Y-mAbs Therapeutics NASDAQ:YMAB

$4.31 -0.01 (-0.23%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$4.35 +0.04 (+0.93%)
As of 07/18/2025 05:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.